Longeveron Inc. (NASDAQ:LGVN) Q3 2023 Earnings Conference Call November 10, 2023 8:30 AM ET

Company Participants

Mike Moyer - Managing Director, LifeSci Advisors, LLC

Wa’el Hashad - CEO

Nataliya Agafonova - CMO

Lisa Locklear - CFO

Joshua M. Hare - Co-Founder, Chief Science Officer and Chairman

Conference Call Participants

Michael Okunewitch - Maxim Group

Operator

Greetings, and welcome to the Longeveron’s Third Quarter 2023 Earnings call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions]. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mike Moyer. Mike, please proceed.

Mike Moyer

Thank you, operator. Good morning, everyone and welcome to Longeveron’s third quarter 2023 results conference call. Today we will discuss financial results for the quarter ended September 30, 2023 and provide a business update. Earlier this morning, we issued a press release with these results, which can be found under the Investor section of Longeveron’s website.

I am joined today by the following members of Longeveron’s management team. Mr. Wa’el Hashad, Chief Executive Officer; Nataliya Agafonova, Chief Medical Officer; and Lisa Locklear, Chief Financial Officer. Mr. Hashad will begin with a brief corporate overview then Dr. Agafonova will review Longeveron’s recent progress in its clinical programs; and Ms. Locklear will review financial results for the third quarter. Following the company’s prepared remarks, we will open the call to questions from covering analysts.

As a reminder, during this call, we will be making forward-looking statements, which are subject to various risks and uncertainties that could cause our actual results to differ materially from these statements. Any such statements should be considered in conjunction with cautionary statements in our press releases and risk factors discussed in our filings with the SEC, including our quarterly report on Form 10-Q and Annual Report on Form 10-K and cautionary statements made during this call. We assume no obligation to update any of these forward-looking statements or information. Now I’d like to turn the call over to Mr. Wa’el Hashad, Chief Executive Officer of Longeveron. Wa’el?

Wa’el Hashad

Thank you Mike and good morning everyone. Welcome to the Longeveron third quarter 2023 business update and financial results call. We are pleased to be speaking with you today and look forward to sharing our progress developing regenerative medicines for unmet medical needs. Our third quarter and recent weeks have been very productive led by top line results we announced from the Clear Mind Alzheimer Disease Trial, which affirms the safety profile of Lomecel-B and provided a clear efficacy signal. We are also presenting extended survival data from ELPIS I trial of Lomecel-B in Hypoplastic Left Heart Syndrome, also known as HLHS at the scientific session of the American Heart Association and took steps to strengthen our balance sheet securing $4 million gross proceeds before expenses from equity financing to support our continued advancement of these clinical programs.